Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.
Lin JJ, Horan JC, Tangpeerachaikul A, Swalduz A, Valdivia A, Johnson ML, Besse B, Camidge DR, Fujino T, Yoda S, Nguyen-Phuong L, Mizuta H, Bigot L, Nobre C, Lee JB, Yu MR, Mente S, Sun Y, Kohl NE, Porter JR, Shair MD, Zhu VW, Felip E, Cho BC, Friboulet L, Hata AN, Pelish HE, Drilon A. Lin JJ, et al. Among authors: nobre c. Cancer Discov. 2024 Sep 13:OF1-OF20. doi: 10.1158/2159-8290.CD-24-0231. Online ahead of print. Cancer Discov. 2024. PMID: 39269178
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
Chen J, Facchinetti F, Braye F, Yurchenko AA, Bigot L, Ponce S, Planchard D, Gazzah A, Nikolaev S, Michiels S, Vasseur D, Lacroix L, Tselikas L, Nobre C, Olaussen KA, Andre F, Scoazec JY, Barlesi F, Soria JC, Loriot Y, Besse B, Friboulet L. Chen J, et al. Among authors: nobre c. Ann Oncol. 2022 Apr;33(4):434-444. doi: 10.1016/j.annonc.2022.01.004. Epub 2022 Jan 21. Ann Oncol. 2022. PMID: 35066105 Free article. Clinical Trial.
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.
Bigot L, Sabio J, Poiraudeau L, Annereau M, Menssouri N, Helissey C, Déas O, Aglave M, Ibrahim T, Pobel C, Nobre C, Nicotra C, Ngo-Camus M, Lacroix L, Rouleau E, Tselikas L, Judde JG, Chauchereau A, Bernard-Tessier A, Patrikidou A, Naoun N, Flippot R, Colomba E, Fuerea A, Albiges L, Lavaud P, Massard C, Friboulet L, Fizazi K, Besse B, Scoazec JY, Loriot Y. Bigot L, et al. Among authors: nobre c. Eur Urol Oncol. 2024 Jun;7(3):527-536. doi: 10.1016/j.euo.2023.10.011. Epub 2023 Oct 27. Eur Urol Oncol. 2024. PMID: 38433714
Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies.
Facchinetti F, Loriot Y, Braye F, Vasseur D, Bahleda R, Bigot L, Barbé R, Nobre C, Combarel D, Michiels S, Italiano A, Smolenschi C, Tselikas L, Scoazec JY, Ponce-Aix S, Besse B, Andre F, Olaussen KA, Hollebecque A, Friboulet L. Facchinetti F, et al. Among authors: nobre c. Clin Cancer Res. 2024 Sep 3:10.1158/1078-0432.CCR-24-1834. doi: 10.1158/1078-0432.CCR-24-1834. Online ahead of print. Clin Cancer Res. 2024. PMID: 39226398 Free PMC article.
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.
Vasseur D, Bigot L, Beshiri K, Flórez-Arango J, Facchinetti F, Hollebecque A, Tselikas L, Aldea M, Blanc-Durand F, Gazzah A, Planchard D, Lacroix L, Pata-Merci N, Nobre C, Da Silva A, Nicotra C, Ngo-Camus M, Braye F, Nikolaev SI, Michiels S, Jules-Clement G, Olaussen KA, André F, Scoazec JY, Barlesi F, Ponce S, Soria JC, Besse B, Loriot Y, Friboulet L. Vasseur D, et al. Among authors: nobre c. Mol Cancer. 2024 Oct 4;23(1):221. doi: 10.1186/s12943-024-02134-4. Mol Cancer. 2024. PMID: 39363320 Free PMC article.
Nasal filling guided by high frequency ultrasound: Reducing risks.
Bravo BSF, Carvalho RM, Elias MC, Nobre CS, Alves GLT, Bravo LG, de Almeida TSC. Bravo BSF, et al. Among authors: nobre cs. J Cosmet Dermatol. 2024 Oct;23(10):3256-3262. doi: 10.1111/jocd.16430. Epub 2024 Jul 3. J Cosmet Dermatol. 2024. PMID: 38958454
180 results